FDA Greenlights First-Ever Drug for Chronic Hepatitis Delta Virus

Chronic hepatitis delta virus infection has long represented one of the most challenging problems in viral hepatology. HDV is a defective virus that requires the hepatitis B surface antigen to replicate, meaning it only affects individuals co-infected or super-infected with hepatitis B. HDV is widely recognized as accelerating progression to cirrhosis, liver failure, and hepatocellular carcinoma compared with hepatitis B alone.

According to a JAMA news item by Anderer published June 12, 2026, the FDA has approved the first treatment specifically for chronic HDV infection. Prior to this action, no therapy had been formally approved by the FDA for HDV in the United States, although other regulatory agencies (notably the EMA) had previously granted conditional approval to bulevirtide in 2020.

Important caveat: only the article title and citation are available in the provided source material. The specific drug approved, the pivotal trial data supporting the approval, efficacy endpoints, safety profile, dosing, and any approval conditions are not contained in the material reviewed here and cannot be summarized without access to the full JAMA news report or the FDA approval documents.

For clinicians, the practical implication — once the drug identity and labeling are confirmed from the full article — is that patients with confirmed chronic HDV infection now have a formally FDA-approved therapeutic option in the U.S., where previously management relied on off-label use of agents such as pegylated interferon-alpha. HDV remains under-screened among hepatitis B carriers, and the availability of an approved therapy may strengthen the rationale for systematic HDV testing in this population, though any guideline changes will depend on subsequent society recommendations.